Isolagen, Inc. Receives Notice of Hearing from American Stock Exchange
16 Julho 2008 - 10:00AM
PR Newswire (US)
EXTON, Pa., July 16 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc.
(AMEX: ILE) announced today that it has received a notice from the
American Stock Exchange scheduling its oral hearing for Tuesday,
August 19, 2008. The notice is in response to the Company's request
for the Exchange to review its determination to begin delisting
proceedings for Isolagen common stock. There can be no assurance
that the Company's request for continued listing will be granted
after such hearing. About Isolagen, Inc. Isolagen(TM), Inc.
(AMEX:ILE) is an aesthetic and therapeutic company committed to
developing and commercializing scientific advances and innovative
technologies. The company's technology platform includes the
Isolagen Process(TM), a cell processing system for skin and tissue
rejuvenation which is currently in clinical development for a broad
range of aesthetic and therapeutic applications including wrinkles,
acne scars, burns and periodontal disease. Isolagen also
commercializes a scientifically-advanced line of skincare systems
through its majority-owned subsidiary, Agera(R) Laboratories, Inc.
For additional information, please visit http://www.isolagen.com/.
Isolagen Forward Looking Statements All statements in this news
release that are not based on historical fact are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. While management has
based any forward-looking statements contained herein on its
current expectations, the information on which such expectations
were based may change. These forward-looking statements rely on a
number of assumptions concerning future events and are subject to a
number of risks, uncertainties, and other factors, many of which
are outside of our control, that could cause actual results to
materially differ from such statements. Such risks, uncertainties,
and other factors include, but are not necessarily limited to,
those set forth under Item 1A Risk Factors in the Company's Annual
Report on Form 10-K for the year ended December 31, 2007, as
updated in Item 1A. Risk Factors in the Company's Quarterly Reports
on Form 10-Q. We operate in a highly competitive and rapidly
changing environment, thus new or unforeseen risks may arise.
Accordingly, investors should not place any reliance on
forward-looking statements as a prediction of actual results. We
disclaim any intention to, and undertake no obligation to, update
or revise any forward-looking statements. Readers are also urged to
carefully review and consider the other various disclosures in the
Company's Annual Report on Form 10-K for the year ended December
31, 2007, as well as other public filings with the SEC since such
date. DATASOURCE: Isolagen, Inc. CONTACT: Mike Beyer of Sam Brown
Inc., for Isolagen, Inc., +1-773-463-4211, Web Site:
http://www.isolagen.com/
Copyright
Isolagen (AMEX:ILE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Isolagen (AMEX:ILE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Isolagen da American Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Isolagen,